Current Opinion in Chemical Biology, Volume 64, October 2021,
Amyloid proteins can aggregate into insoluble fibrils and form amyloid deposits in the human brain, which is the hallmark of many neurodegenerative diseases. Promising strategies toward pathological amyloid proteins and deposition include investigating inhibitors that can disrupt amyloid aggregation or induce misfolding protein degradation. In this review, recent progress of peptide-based inhibitors, including amyloid sequence–derived inhibitors, designed peptides, and peptide mimics, is highlighted. Based on the increased understanding of peptide design and precise amyloid structures, these peptides exhibit advanced inhibitory activities against fibrous aggregation as well as enhanced druggability.
Aggregation; Amyloid; Amyloid Protein; Blood Brain Barrier; Cyclization; Cyclopeptide; Degenerative Disease; Drug Design; Human; Molecular Mimicry; Peptide; Peptide Inhibitor; Protein Aggregation; Protein Degradation; Protein Inhibitor; Protein Modification; Protein Secondary Structure; Protein Structure; Review; Water Solubility; Global